Skip to main content

Bio-Techne Corp Value Stock - Dividend - Research Selection

Bio-techne

ISIN: US09073M1045 , WKN: A12ENG

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, and diagnostics and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment provides biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment provides diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and nucleic acid analysis products for use in diagnostic or research applications, as well as instruments and process control products for hematology, blood chemistry, blood gases, and coagulation controls and reagents used in various diagnostic applications. It offers its products under R&D Systems, Novus Biologicals, Tocris Biosciences, ProteinSimple, Advanced Cell Diagnostics, and ExosomeDx brands. Bio-Techne Corporation has a clinical research collaboration with Carterra Inc. for the study of COVID-19 variants. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Q4 Research Tools & Consumables Earnings: Bio-Techne (NASDAQ:TECH) Earns Top Marks

2026-03-26
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q4. Today, we are looking at research tools & consumables stocks, starting with Bio-Techne (NASDAQ:TECH).

Bio-Techne Advances Spatial Biology with Modular Expansion of COMET™ Suite

2026-03-25
Bio-Techne Corporation (NASDAQ: TECH), a global provider of life science tools, reagents and diagnostic products, today announced the expansion of its COMET™ solution portfolio with the addition of the new SPYRE™ Focus Panels and SPYRE™ Amplification Kits. Together, these strengthen the COMET technology modular, automated spatial biology workflow, delivering expanded flexibility, greater sensitivity, and enabling deeper, more focused interrogation of biologically meaningful data from initial ass

Bio-Techne Expands COMET Solution Portfolio With Addition Of New SPYRE Focus Panels And SPYRE Amplification Kits

2026-03-25
New SPYRE™ Focus Panels (Stroma and Vessel) broaden modular panel options, enabling deeper targeted insights in spatial biology workflows.  SPYRE™ Amplification Kits leverage sequential

How Is Bio-Techne's Stock Performance Compared to Other Biotechnology Stocks

2026-03-20
Bio-Techne has underperformed other biotechnology stocks over the past year, yet analysts remain moderately optimistic about the stock’s growth potential.

Evolve Announces March 2026 Distributions for UltraYield ETFs and Certain Evolve Funds

2026-03-18
Toronto, Ontario--(Newsfile Corp. - March 18, 2026) - Evolve Funds Group Inc. ("Evolve") is pleased to announce the distribution amounts per unit (the "Distributions") for certain funds (the "UltraYield ETFs" and "Evolve Funds"), as indicated in the tables below.The ex-dividend dates and record dates for the Distributions of UltraYield ETFs including the Evolve US Equity UltraYield ETF ("BIGY"), Evolve Canadian Equity UltraYield ETF ("CANY"), Evolve Big Six Canadian Banks UltraYield Index ETF...

Should You Continue to Hold Bio-Techne Stock in Your Portfolio?

2026-03-17
TECH expands via acquisitions and global growth, but biotech funding softness, U.S. academic spending pressure and competition cloud near-term outlook.

Exploring the top movers within the S&P500 index during today's session.

2026-03-16
Stay updated with the movements of the S&P500 index one hour before the close of the markets on Monday. Discover which stocks are leading as top gainers and losers in today's session.

Stay informed with the top movers within the S&P500 index on Monday.

2026-03-16
Curious about the top performers within the S&P500 index in the middle of the day on Monday? Dive into the list of today's session's top gainers and losers for a comprehensive overview.

Assessing Bio‑Techne (TECH) Valuation After Institutional Buying Earnings Beat And New AI Drug Discovery Push

2026-03-13
Bio-Techne (TECH) is back in focus after institutional investors such as Jefferies Financial Group and Madison Investments increased their exposure, alongside earnings that topped expectations and fresh AI collaborations in drug discovery. See our latest analysis for Bio-Techne. Despite upbeat earnings and fresh AI partnerships, Bio-Techne’s recent share price performance has been weak, with a 30 day share price return of a 19.9% decline and a 1 year total shareholder return of a 17.7% loss...

Is Bio-Techne Stock a Buy, Sell, or Hold After a Wealth Manager Dumps Its Entire Stake?

2026-03-13
Bio-Techne develops specialized reagents and diagnostic solutions for global research and clinical markets in the life sciences sector.